Advanced Cancer Diagnostics Market
Advanced Cancer Diagnostics Market Forecasts to 2032 – Global Analysis By Product Type (Instruments, Consumables, Software & Services, and Other Product Types), Cancer Type, Technology, Distribution Channel, Application, End User and By Geography
According to Stratistics MRC, the Global Advanced Cancer Diagnostics Market is accounted for $64.13 billion in 2025 and is expected to reach $124.97 billion by 2032 growing at a CAGR of 10.0% during the forecast period. Advanced cancer diagnostics encompass modern techniques and technologies used to identify cancers early, analyze tumor biology, and personalize treatment decisions. They involve tools such as biomarker analysis, genetic testing, advanced imaging, and molecular profiling. These diagnostic methods allow for accurate cancer detection, improved prognosis, and reduced treatment complications. By supporting targeted therapy development and precise intervention, advanced diagnostics significantly enhance patient care, survival chances, and overall treatment effectiveness.
Market Dynamics:
Driver:
Rising global cancer incidence
As aging populations grow and lifestyle-related risk factors increase, early detection technologies are becoming essential in clinical workflows. Healthcare systems are investing in precision oncology tools, including liquid biopsies and molecular imaging, to improve diagnostic accuracy. Innovations in AI-powered pathology and next-generation sequencing (NGS) are enabling personalized treatment strategies. The integration of multi-omics platforms is transforming cancer diagnostics into a data-driven discipline. This rising burden of cancer is catalyzing market expansion across both developed and emerging economies.
Restraint:
Complex and restrictive reimbursement policies
Reimbursement frameworks for advanced cancer diagnostics remain fragmented and often hinder widespread adoption. Payers frequently require extensive clinical validation and cost-effectiveness data before approving coverage for novel diagnostic tests. The inclusion of AI and genomic technologies adds regulatory complexity, slowing reimbursement approvals. Smaller diagnostic firms face challenges navigating these policies due to limited resources and expertise. These constraints can delay patient access to cutting-edge diagnostic tools and stifle innovation. Harmonizing global reimbursement standards is critical to unlocking the full potential of precision diagnostics.
Opportunity:
Expanding diagnostic capabilities
Rapid advancements in diagnostic technologies are opening new frontiers in cancer detection and monitoring. Liquid biopsy platforms, AI-enhanced imaging, and real-time biomarker analysis are revolutionizing how clinicians identify malignancies. The shift toward non-invasive and point-of-care diagnostics is improving patient comfort and operational efficiency. Emerging trends include wearable biosensors and cloud-based diagnostic platforms that enable remote cancer screening. Regulatory bodies are increasingly supporting innovation through expedited approval pathways and digital health initiatives. These developments are creating fertile ground for market growth and cross-sector collaboration.
Threat:
Risk of false positives/negatives
False positives can lead to unnecessary treatments and psychological distress, while false negatives may delay life-saving interventions. Variability in test sensitivity and specificity across platforms contributes to inconsistent outcomes. AI algorithms, while promising, require rigorous validation to ensure clinical reliability. Regulatory agencies are tightening standards around diagnostic performance and data transparency. Addressing these risks is vital to maintaining trust and ensuring the safe integration of emerging technologies.
Covid-19 Impact:
The COVID-19 pandemic disrupted cancer diagnostic services, delaying screenings and reducing patient throughput. Lockdowns and resource reallocation strained laboratory operations and supply chains, leading to test shortages. However, the crisis accelerated the adoption of remote diagnostics, telepathology, and AI-driven triage systems. Emergency use authorizations enabled faster deployment of innovative diagnostic tools during the pandemic. Post-COVID strategies now emphasize resilience, automation, and decentralized testing models. These shifts are reshaping the cancer diagnostics landscape with a stronger focus on digital transformation and preparedness.
The consumables segment is expected to be the largest during the forecast period
The consumables segment is expected to account for the largest market share during the forecast period, due to its indispensable role in routine diagnostic procedures. Reagents, assay kits, and sample preparation tools are critical for molecular and immunohistochemical testing. Continuous innovation in reagent formulations and microfluidic cartridges is enhancing test sensitivity and throughput. The rise of personalized medicine is driving demand for specialized consumables tailored to individual cancer profiles. Automation in laboratory workflows is boosting consumable usage across centralized and decentralized settings. As diagnostic volumes increase globally, consumables remain the backbone of cancer testing infrastructure.
The hospitals & clinics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the hospitals & clinics segment is predicted to witness the highest growth rate, driven by their central role in cancer diagnosis and treatment. These facilities are rapidly adopting advanced imaging systems, AI-based pathology tools, and integrated diagnostic platforms. The push for early detection and precision oncology is fueling investment in in-house diagnostic capabilities. Hospitals are also leveraging cloud-based data analytics to streamline workflows and enhance diagnostic accuracy. Emerging trends include hybrid diagnostic labs and multidisciplinary cancer centers equipped with real-time decision support systems. As patient volumes rise, hospitals and clinics are becoming hubs for innovation in cancer diagnostics.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising cancer prevalence. Countries like China, India, and Japan are investing heavily in diagnostic modernization and local manufacturing. Government initiatives are promoting early cancer screening and subsidizing advanced diagnostic technologies. The region is witnessing rapid adoption of AI-assisted imaging and portable diagnostic devices. Strategic collaborations between global tech firms and regional healthcare providers are accelerating innovation and market penetration.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fueled by its leadership in diagnostic innovation and research funding. The U.S. and Canada are pioneering developments in genomic profiling, AI-powered diagnostics, and smart laboratory systems. Regulatory agencies are streamlining approval processes for cutting-edge diagnostic tools, encouraging faster market entry. Hospitals are integrating IoT and cloud-based platforms to enhance diagnostic precision and operational efficiency. The region benefits from a robust reimbursement ecosystem and high adoption of personalized medicine. As cancer care becomes increasingly data-driven, North America continues to set global benchmarks in diagnostic excellence.
Key players in the market
Some of the key players in Advanced Cancer Diagnostics Market include F. Hoffmann-La Roche Ltd., bioMérieux SA, Thermo Fisher Scientific Inc., Medtronic plc, Abbott Laboratories, Becton, Dickinson and Company (BD), Illumina Inc., Myriad Genetics Inc., GE Healthcare, Guardant Health, Siemens Healthineers, Qiagen N.V., Bio-Rad Laboratories Inc., Hologic Inc., and Agilent Technologies Inc.
Key Developments:
In September 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio’s pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients as well as cirrhotic patients.
In June 2025, bioMérieux announced an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance bioMérieux's capabilities in next-generation sequencing (NGS) and rapid diagnostics, further solidifying its commitment to advancing healthcare and Antimicrobial Stewardship through innovative solutions.
Product Types Covered:
• Instruments
• Consumables
• Software and Services
• Other Product Types
Cancer Types Covered:
• Breast Cancer
• Liver Cancer
• Lung Cancer
• Cervical Cancer
• Colorectal Cancer
• Ovarian Cancer
• Prostate Cancer
• Other Cancers
Technologies Covered:
• Imaging Techniques
• Molecular Diagnostics
• Immunoassays
• Liquid Biopsy
• Other Technologies
Distribution Channels Covered:
• Direct Sales
• Distributors & Dealers
• Online Platforms
Applications Covered:
• Early Cancer Screening
• Recurrence & Minimal Residual Disease (MRD) Detection
• Diagnostic & Prognostic Testing
• Companion Diagnostics
• Therapy Selection & Monitoring
• Other Applications
End Users Covered:
• Hospitals & Clinics
• Ambulatory Care Centers
• Diagnostic Laboratories
• Cancer Research Institutes
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 End User Analysis
3.10 Emerging Markets
3.11 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Advanced Cancer Diagnostics Market, By Product Type
5.1 Introduction
5.2 Instruments
5.2.1 Imaging Systems
5.2.2 Pathology-based Instruments
5.2.3 Molecular Diagnostic Platforms
5.3 Consumables
5.3.1 Kits & Reagents
5.3.2 Assay Panels
5.4 Software & Services
5.4.1 Data Analytics Tools
5.4.2 Diagnostic Services
5.5 Other Product Types
6 Global Advanced Cancer Diagnostics Market, By Cancer Type
6.1 Introduction
6.2 Breast Cancer
6.3 Liver Cancer
6.4 Lung Cancer
6.5 Cervical Cancer
6.6 Colorectal Cancer
6.7 Ovarian Cancer
6.8 Prostate Cancer
6.9 Other Cancers
7 Global Advanced Cancer Diagnostics Market, By Technology
7.1 Introduction
7.2 Imaging Techniques
7.2.1 MRI
7.2.2 PET/CT
7.2.3 CT Scan
7.2.4 Ultrasound
7.2.5 Mammography
7.3 Molecular Diagnostics
7.3.1 PCR
7.3.2 Microarrays
7.3.3 Next-Generation Sequencing (NGS)
7.3.4 In Situ Hybridization (ISH)
7.4 Immunoassays
7.4.1 ELISA
7.4.2 Immunohistochemistry (IHC)
7.5 Liquid Biopsy
7.5.1 Circulating Tumor Cells (CTCs)
7.5.2 Circulating Tumor DNA (ctDNA)
7.5.3 Exosomes
7.6 Other Technologies
8 Global Advanced Cancer Diagnostics Market, By Distribution Channel
8.1 Introduction
8.2 Direct Sales
8.3 Distributors & Dealers
8.4 Online Platforms
9 Global Advanced Cancer Diagnostics Market, By Application
9.1 Introduction
9.2 Early Cancer Screening
9.3 Recurrence & Minimal Residual Disease (MRD) Detection
9.4 Diagnostic & Prognostic Testing
9.5 Companion Diagnostics
9.6 Therapy Selection & Monitoring
9.7 Other Applications
10 Global Advanced Cancer Diagnostics Market, By End User
10.1 Introduction
10.2 Hospitals & Clinics
10.3 Ambulatory Care Centers
10.4 Diagnostic Laboratories
10.5 Cancer Research Institutes
10.6 Other End Users
11 Global Advanced Cancer Diagnostics Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 F. Hoffmann-La Roche Ltd.
13.2 bioMérieux SA
13.3 Thermo Fisher Scientific Inc.
13.4 Medtronic plc
13.5 Abbott Laboratories
13.6 Becton, Dickinson and Company (BD)
13.7 Illumina Inc.
13.8 Myriad Genetics Inc.
13.9 GE Healthcare
13.10 Guardant Health
13.11 Siemens Healthineers
13.12 Qiagen N.V.
13.13 Bio-Rad Laboratories Inc.
13.14 Hologic Inc.
13.15 Agilent Technologies Inc.
List of Tables
1 Global Advanced Cancer Diagnostics Market Outlook, By Region (2024-2032) ($MN)
2 Global Advanced Cancer Diagnostics Market Outlook, By Product Type (2024-2032) ($MN)
3 Global Advanced Cancer Diagnostics Market Outlook, By Instruments (2024-2032) ($MN)
4 Global Advanced Cancer Diagnostics Market Outlook, By Imaging Systems (2024-2032) ($MN)
5 Global Advanced Cancer Diagnostics Market Outlook, By Pathology-based Instruments (2024-2032) ($MN)
6 Global Advanced Cancer Diagnostics Market Outlook, By Molecular Diagnostic Platforms (2024-2032) ($MN)
7 Global Advanced Cancer Diagnostics Market Outlook, By Consumables (2024-2032) ($MN)
8 Global Advanced Cancer Diagnostics Market Outlook, By Kits & Reagents (2024-2032) ($MN)
9 Global Advanced Cancer Diagnostics Market Outlook, By Assay Panels (2024-2032) ($MN)
10 Global Advanced Cancer Diagnostics Market Outlook, By Software & Services (2024-2032) ($MN)
11 Global Advanced Cancer Diagnostics Market Outlook, By Data Analytics Tools (2024-2032) ($MN)
12 Global Advanced Cancer Diagnostics Market Outlook, By Diagnostic Services (2024-2032) ($MN)
13 Global Advanced Cancer Diagnostics Market Outlook, By Other Product Types (2024-2032) ($MN)
14 Global Advanced Cancer Diagnostics Market Outlook, By Cancer Type (2024-2032) ($MN)
15 Global Advanced Cancer Diagnostics Market Outlook, By Breast Cancer (2024-2032) ($MN)
16 Global Advanced Cancer Diagnostics Market Outlook, By Liver Cancer (2024-2032) ($MN)
17 Global Advanced Cancer Diagnostics Market Outlook, By Lung Cancer (2024-2032) ($MN)
18 Global Advanced Cancer Diagnostics Market Outlook, By Cervical Cancer (2024-2032) ($MN)
19 Global Advanced Cancer Diagnostics Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
20 Global Advanced Cancer Diagnostics Market Outlook, By Ovarian Cancer (2024-2032) ($MN)
21 Global Advanced Cancer Diagnostics Market Outlook, By Prostate Cancer (2024-2032) ($MN)
22 Global Advanced Cancer Diagnostics Market Outlook, By Other Cancers (2024-2032) ($MN)
23 Global Advanced Cancer Diagnostics Market Outlook, By Technology (2024-2032) ($MN)
24 Global Advanced Cancer Diagnostics Market Outlook, By Imaging Techniques (2024-2032) ($MN)
25 Global Advanced Cancer Diagnostics Market Outlook, By MRI (2024-2032) ($MN)
26 Global Advanced Cancer Diagnostics Market Outlook, By PET/CT (2024-2032) ($MN)
27 Global Advanced Cancer Diagnostics Market Outlook, By CT Scan (2024-2032) ($MN)
28 Global Advanced Cancer Diagnostics Market Outlook, By Ultrasound (2024-2032) ($MN)
29 Global Advanced Cancer Diagnostics Market Outlook, By Mammography (2024-2032) ($MN)
30 Global Advanced Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2024-2032) ($MN)
31 Global Advanced Cancer Diagnostics Market Outlook, By PCR (2024-2032) ($MN)
32 Global Advanced Cancer Diagnostics Market Outlook, By Microarrays (2024-2032) ($MN)
33 Global Advanced Cancer Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
34 Global Advanced Cancer Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2024-2032) ($MN)
35 Global Advanced Cancer Diagnostics Market Outlook, By Immunoassays (2024-2032) ($MN)
36 Global Advanced Cancer Diagnostics Market Outlook, By ELISA (2024-2032) ($MN)
37 Global Advanced Cancer Diagnostics Market Outlook, By Immunohistochemistry (IHC) (2024-2032) ($MN)
38 Global Advanced Cancer Diagnostics Market Outlook, By Liquid Biopsy (2024-2032) ($MN)
39 Global Advanced Cancer Diagnostics Market Outlook, By Circulating Tumor Cells (CTCs) (2024-2032) ($MN)
40 Global Advanced Cancer Diagnostics Market Outlook, By Circulating Tumor DNA (ctDNA) (2024-2032) ($MN)
41 Global Advanced Cancer Diagnostics Market Outlook, By Exosomes (2024-2032) ($MN)
42 Global Advanced Cancer Diagnostics Market Outlook, By Other Technologies (2024-2032) ($MN)
43 Global Advanced Cancer Diagnostics Market Outlook, By Distribution Channel (2024-2032) ($MN)
44 Global Advanced Cancer Diagnostics Market Outlook, By Direct Sales (2024-2032) ($MN)
45 Global Advanced Cancer Diagnostics Market Outlook, By Distributors & Dealers (2024-2032) ($MN)
46 Global Advanced Cancer Diagnostics Market Outlook, By Online Platforms (2024-2032) ($MN)
47 Global Advanced Cancer Diagnostics Market Outlook, By Application (2024-2032) ($MN)
48 Global Advanced Cancer Diagnostics Market Outlook, By Early Cancer Screening (2024-2032) ($MN)
49 Global Advanced Cancer Diagnostics Market Outlook, By Recurrence & Minimal Residual Disease (MRD) Detection (2024-2032) ($MN)
50 Global Advanced Cancer Diagnostics Market Outlook, By Diagnostic & Prognostic Testing (2024-2032) ($MN)
51 Global Advanced Cancer Diagnostics Market Outlook, By Companion Diagnostics (2024-2032) ($MN)
52 Global Advanced Cancer Diagnostics Market Outlook, By Therapy Selection & Monitoring (2024-2032) ($MN)
53 Global Advanced Cancer Diagnostics Market Outlook, By Other Applications (2024-2032) ($MN)
54 Global Advanced Cancer Diagnostics Market Outlook, By End User (2024-2032) ($MN)
55 Global Advanced Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
56 Global Advanced Cancer Diagnostics Market Outlook, By Ambulatory Care Centers (2024-2032) ($MN)
57 Global Advanced Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
58 Global Advanced Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2024-2032) ($MN)
59 Global Advanced Cancer Diagnostics Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
